Search

Your search keyword '"Azouz, Amany A."' showing total 38 results
Start Over Author "Azouz, Amany A."
38 results on '"Azouz, Amany A."'

10. Design and construction of novel pyridine-pyrimidine hybrids as selective COX-2 suppressors: anti-inflammatory potential, ulcerogenic profile, molecular modeling and ADME/Tox studies

Author

Shaker, Mohamed E., primary, Goma, Hesham A. M., additional, Alsalahat, Izzeddin, additional, Elkanzi, Nadia A. A., additional, Azouz, Amany A., additional, Abdel-Bakky, Mohamed Sadek, additional, Ghoneim, Mohammed M., additional, Hazem, Sara H., additional, El-Mesery, Mohamed E., additional, Farouk, Amr, additional, Alzarea, Sami I., additional, Alsahli, Tariq G., additional, Alotaibi, Nasser Hadal, additional, Musa, Arafa, additional, Abdelgawad, Mohamed A., additional, and Bakr, Rania B., additional

Published
2023
Full Text
View/download PDF

17. Balancing renal Ang-II/Ang-(1–7) by xanthenone; an ACE2 activator; contributes to the attenuation of Ang-II/p38 MAPK/NF-κB p65 and Bax/caspase-3 pathways in amphotericin B-induced nephrotoxicity in rats.

Author

Azouz, Amany A., Abdel-Rahman, Doaa M., and Messiha, Basim Anwar Shehata

Subjects
*AMPHOTERICIN B, *ANGIOTENSIN converting enzyme, *NEPHROTOXICOLOGY, *CYSTATIN C, *BIOMARKERS, *ANTIFUNGAL agents
Abstract

Despite the great importance of amphotericin B for the management of life-threatening systemic fungal infections, its nephrotoxic effect restricts its repeated administration. This study was designed to examine the prospective modulatory effects of xanthenone, an ACE2 activator, against amphotericin B nephrotoxicity. Male Wistar rats were allocated into four groups; control (1st), Xanthenone (2nd), Amphotericin B (3rd), and Xanthenone + Amphotericin B (4th). The second and fourth groups received xanthenone (2 mg/kg; s.c.) daily for 14 consecutive days. Amphotericin B (18.5 mg/kg; i.p.) was administered to the third and fourth groups daily starting from day 8. After 2 weeks, samples were withdrawn for analysis. The histopathological findings, molecular and biochemical markers showed that amphotericin B caused marked renal injury. Pretreatment with xanthenone ameliorated amphotericin B-induced deterioration in kidney function biomarkers (creatinine, urea, cystatin C, KIM-1) and guarded against the disturbance of serum electrolytes (Na+, K+, Mg2+) due to amphotericin B-induced tubular dysfunction. Besides, the ACE2 activator xanthenone-balanced renal Ang-II/Ang-(1–7), and so the inflammatory signaling p38 MAPK/NF-κB p65 and its downstream inflammatory cytokines (TNF-α, IL-6) were attenuated. Meanwhile, the anti-oxidant signaling Nrf2/HO-1 and glutathione content were preserved, but the lipid peroxidation marker MDA was declined. These regulatory effects of xanthenone eventually enhanced Bcl-2 (anti-apoptotic), but reduced Bax (pro-apoptotic) and cleaved caspase-3 (apoptotic executioner) protein expressions. Collectively, the regulatory effects of xanthenone on renal Ang-II/Ang-(1–7) could at least partially contribute to the mitigation of amphotericin B nephrotoxicity by attenuating inflammatory signaling, oxidative stress, and apoptosis, thus improving the tolerability to amphotericin B. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Docking Study, Synthesis, and Anti-Inflammatory Potential of Some New Pyridopyrimidine-Derived Compounds

Author

Abdelgawad,Mohamed A, Al-Sanea,Mohammad, Musa,Arafa, Elmowafy,Mohammed, El-Damasy,Ashraf K, Azouz,Amany A, Ghoneim,Mohammed M, Bakr,Rania B, Abdelgawad,Mohamed A, Al-Sanea,Mohammad, Musa,Arafa, Elmowafy,Mohammed, El-Damasy,Ashraf K, Azouz,Amany A, Ghoneim,Mohammed M, and Bakr,Rania B

Abstract

Mohamed A Abdelgawad,1 Mohammad M Al-Sanea,1 Arafa Musa,2 Mohammed Elmowafy,3 Ashraf K El-Damasy,4 Amany A Azouz,5 Mohammed M Ghoneim,6 Rania B Bakr7 1Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 72341, Saudi Arabia; 2Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, 72341, Saudi Arabia; 3Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia; 4Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt; 5Department of Pharmacology and Toxicology, Beni-Suef University, Beni-Suef, 62514, Egypt; 6Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, 13713, Saudi Arabia; 7Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni- Suef, 62514, EgyptCorrespondence: Mohamed A Abdelgawad, Tel +966595435214, Fax +966-14 2317958, Email mhmdgwd@ju.edu.sa; mohamedabdelwahab976@yahoo.comBackground and Purpose: Because of gastrointestinal irritation and kidney toxicity associated with non-steroidal anti-inflammatory drugs and the cardiovascular problems of Coxibs use, developing novel anti-inflammatory agents with reduced toxicity and improved selectivity remains a major challenge. Depending on our previous work, a novel series of pyridopyrimidinones IIIa-i has been synthesized via reaction of 6-amino-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one (I) and phenyldiazenyl aromatic aldehydes (IIa-i). All the new constructed compounds were fully characterized by elemental and spectral analysis.Methods: The target compounds IIIa–i were investigated for their potential towards COX inhibition, anti-inflammatory properties using carrageenan induced edema model in rat paw, and the ulcer indices of the most active members.Results: The ethyl pyridopyrmidinone-benzoates IIIf, IIIg and IIIh showed superior inhibitory activity of carrageenan induced edema to celecoxib. Furt

Published
2022

38. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4- d ]pyrimidine derivatives.

Author

Bakr, Rania B., Azouz, Amany A., and Abdellatif, Khaled R. A.

Subjects
*CYCLOOXYGENASE inhibitors, *ANTI-inflammatory agents, *DRUG synthesis, *PHENYLPYRAZOLES, *PYRIMIDINE derivatives
Abstract

A new group of 1-phenylpyrazolo[3,4-d]pyrimidine derivatives14a–d–21were synthesized from 2-(6-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)acetohydrazide (12). All the synthesized compounds were evaluated for their cyclooxygenase (COX) inhibition, anti-inflammatory activity and ulcerogenic liability. All the target compounds were more potential in inhibiting COX-2 than COX-1. Compounds having pyrazolyl moiety in a hybrid structure with pyrazolo[3,4-d]pyrimidine scaffold (14a–d,16and17) showed higher edema inhibition percentage activities (34–68%) and the 5-aminopyrazole derivative (14c, ED50 = 87.9 μmol/kg) was the most potent one > celecoxib (ED50 = 91.9 μmol/kg). While, thein vivopotent compounds (14a–d,16,17and21) caused variable ulceration effect (ulcer index = 0.33–4.0) comparable to that of celecoxib (ulcer index = 0.33), the pyrazol-3-one derivative (16)and the acetohydrazide (21) were the least ulcerogenic derivatives showing the same ulcerogenic potential of celecoxib. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results